Loading...
Market
Will FTC file formal charges against CVS, UnitedHealth, or Cigna for drug price markups by July 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FTC press releases or official filings
Story
FTC Accuses CVS, UnitedHealth, Cigna of Marking Up Specialty Drug Prices for Cancer, HIV, Heart Disease, Generating $7.3 Billion
Jan 14, 2025, 05:21 PM
The Federal Trade Commission (FTC) has released a report accusing the three largest pharmacy benefit managers (PBMs) in the U.S.—CVS Health's Caremark, UnitedHealth Group's OptumRx, and Cigna's Express Scripts—of marking up the prices of specialty generic drugs, generating an estimated $7.3 billion in revenue from 2017 to 2022. The report highlights that these PBMs marked up the prices of drugs used to treat serious conditions such as cancer, HIV, and heart disease by hundreds or thousands of percent at their affiliated pharmacies. FTC Chair Lina Khan stated that the agency should continue to investigate practices that may inflate drug costs and act swiftly to stop any illegal conduct. The findings suggest that these markups have contributed to higher overall healthcare costs and have impacted independent pharmacies negatively.
View original story
Similar markets
Other outcomes • 25%
Policy changes mandated • 25%
Fines imposed • 25%
No action taken • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
CVS found liable • 25%
Case dismissed • 25%
CVS settles • 25%
CVS found guilty • 25%
Ongoing litigation • 25%
Other outcome • 25%
No • 50%
Yes • 50%
UnitedHealth’s OptumRx • 33%
None • 1%
Cigna’s Express Scripts • 33%
CVS Health’s Caremark • 33%